FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

16 letters match. Newest first.

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  3. Refills Health, LLC dba Refills Health

    FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.

    Medium
  4. FitRX, LLC dba Zealthy

    FDA warns Zealthy over website claims that compounded semaglutide is the same as Wegovy and Ozempic.

    Medium
  5. ybycmeds

    FDA warns ybycmeds over website claims that compounded semaglutide and tirzepatide are similar to approved brand-name drugs.

    Medium
  6. Try Nova

    FDA warned Try Nova that its website’s compounded semaglutide claim "Same active ingredient as Wegovy & Ozempic" is false or misleading.

    Low
  7. Lovely Meds, Inc. dba Lovely Meds

    FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.

    Low
  8. Lyfe Rx

    Lyfe Rx offered compounded semaglutide and tirzepatide online with false 'clinically proven weight loss' claims, FDA says.

    Low
  9. Hello Cake, Inc. dba Hello Cake

    FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.

    Medium
  10. Sprout Health Partners LLC dba Sprout Health

    FDA warned telehealth seller Sprout Health that its website's claim compounded semaglutide and tirzepatide are FDA-approved makes the drugs misbranded.

    Low
  11. SemaBio

    FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.

    Low
  12. Healthy Male

    FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.

    Low
  13. Invigorate Med Spa

    Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.

    Low
  14. Matthew Stern, CEO MyStart Health LLC.

    FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

    Low
  15. Elite Health Center

    FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.

    Low
  16. Lexion Medical LLC

    Lexion Medical marketed three surgical gas devices for uncleared uses, including COVID-19 protection, without FDA clearance.

    High risk